All treatment groups displayed dosage efficacy via a highly significant reduction (p < 0.001) in the E2 hormone as compared to the disease control group (Figure 9A), whereas for progesterone, the results showed tamoxifen (5 mg/kg) and O-NPAT at both doses of 30 and 60 mg/kg exhibiting a highly significant reduction (p < 0.001) in PR levels in contrast to the disease control group, the tumor characteristics (13.6 ± 0.332 pg/mg) of which are presented in Figure 9B. This evidence concerns the gene PGR and neoplasm.